A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis

ConditionPsoriasis

Trial statusRecruiting

Trial phasePhase 3

Trial typeInterventional

Biological sexAll

Age12-18

SponsorInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

About this trial

The purpose of this study is to evaluate the efficacy and safety of IBI112 in the treatment of adolescent participants with moderate to severe plaque-type psoriasis.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

IBI112
placebo

Treatment groups

104 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

Lead sponsor

Source ClinicalTrials.gov